Literature DB >> 12062359

How to evaluate plaque vulnerability in animal models of atherosclerosis?

Mark D Rekhter1.   

Abstract

Prevention of heart attack and stroke depends on detection of vulnerable plaques and development of plaque-stabilizing therapies. In turn, progress in diagnostics and treatment is contingent on our understanding of molecular mechanisms of plaque vulnerability. Animal models are essential for testing mechanistic hypotheses in a controlled manner. Currently, there is no single, golden standard animal model of a vulnerable plaque. However, the whole range of experimental approaches is readily available. It includes traditional models of atherosclerosis combined with new 'vulnerability endpoints', as well as several models featuring spontaneous or induced plaque rupture/thrombosis. This review summarizes current literature on the animal models of vulnerable atherosclerotic plaques.

Entities:  

Mesh:

Year:  2002        PMID: 12062359     DOI: 10.1016/s0008-6363(01)00537-5

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  23 in total

Review 1.  Vulnerable plaque imaging-current techniques.

Authors:  K Chad Hilty; Daniel H Steinberg
Journal:  J Cardiovasc Transl Res       Date:  2009-01-14       Impact factor: 4.132

2.  Near-infrared fluorescence imaging of murine atherosclerosis using an oxidized low density lipoprotein-targeted fluorochrome.

Authors:  Tong Lu; Song Wen; Ying Cui; Sheng-Hong Ju; King C Li; Gao-Jun Teng
Journal:  Int J Cardiovasc Imaging       Date:  2013-10-30       Impact factor: 2.357

3.  Th17 cells and IL-17 are involved in the disruption of vulnerable plaques triggered by short-term combination stimulation in apolipoprotein E-knockout mice.

Authors:  Tian Ma; Qi Gao; Faliang Zhu; Chun Guo; Qun Wang; Fei Gao; Lining Zhang
Journal:  Cell Mol Immunol       Date:  2013-04-01       Impact factor: 11.530

4.  S100A9-targeted tobacco mosaic virus nanoparticles exhibit high specificity toward atherosclerotic lesions in ApoE-/- mice.

Authors:  Jooneon Park; Huiyun Gao; Yunmei Wang; He Hu; Daniel I Simon; Nicole F Steinmetz
Journal:  J Mater Chem B       Date:  2019-02-13       Impact factor: 6.331

5.  Photosensitizer delivery to vulnerable atherosclerotic plaque: comparison of macrophage-targeted conjugate versus free chlorin(e6).

Authors:  Ahmed Tawakol; Ana P Castano; Florencia Anatelli; Gregory Bashian; Jeremy Stern; Touqir Zahra; Faten Gad; Stephanie Chirico; Atosa Ahmadi; Alan J Fischman; James E Muller; Michael R Hamblin
Journal:  J Biomed Opt       Date:  2006 Mar-Apr       Impact factor: 3.170

6.  In vivo mapping of vascular inflammation using multimodal imaging.

Authors:  Benjamin R Jarrett; Carlos Correa; Kwan Liu Ma; Angelique Y Louie
Journal:  PLoS One       Date:  2010-10-11       Impact factor: 3.240

7.  Progression of arteriovenous bypass restenosis in mice exposed to a 50 Hz magnetic field.

Authors:  Blair Henderson; Andrea Tagwerker; Christina Mayrl; Gerald Pfister; Günther Boeck; Hanno Ulmer; Hermann Dietrich; Georg Wick
Journal:  Cell Stress Chaperones       Date:  2003       Impact factor: 3.667

8.  Historical Incidence of Spontaneous Lesions in Kidneys from Naïve Swine Utilized In Interventional Renal Denervation Studies.

Authors:  Serge D Rouselle; Krista N Dillon; Theo H Rousselle-Sabiac; Dane A Brady; Stefan Tunev; Armando Tellez
Journal:  J Cardiovasc Transl Res       Date:  2016-05-17       Impact factor: 4.132

Review 9.  Atherogenesis: hyperhomocysteinemia interactions with LDL, macrophage function, paraoxonase 1, and exercise.

Authors:  Ilya Chernyavskiy; Sudhakar Veeranki; Utpal Sen; Suresh C Tyagi
Journal:  Ann N Y Acad Sci       Date:  2016-02-05       Impact factor: 5.691

10.  Intravascular imaging of atherosclerotic human coronaries in a porcine model: a feasibility study.

Authors:  Sergio Waxman; Kamal Khabbaz; Raymond Connolly; Jing Tang; Alexandra Dabreo; Lara Egerhei; Fumiyuki Ishibashi; James E Muller; Guillermo M Tearney
Journal:  Int J Cardiovasc Imaging       Date:  2007-05-15       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.